Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review

Advances in Therapy

Volumn 33, Issue 9, 2016, Pages 1502-1518

  Kalra, Sanjay ^a   Singh, Vikram ^b   Nagrale, Dinesh ^b  

^a Bharti Hospital ^*  (India)

^b Johnson and Johnson Limited   (India)

Author keywords

Chronic kidney disease; Diabetes mellitus; Endocrinology; Glomerular hyperfiltration; Glomerulus; Nephrology; Nephroprotection; SGLT2 inhibitors

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ANGIOTENSIN RECEPTOR ANTAGONIST; CANAGLIFLOZIN; DAPAGLIFLOZIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EMPAGLIFLOZIN; GLUCOSE; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; ANTIDIABETIC AGENT;

BLOOD PRESSURE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; GENE EXPRESSION; GLOMERULUS; GLOMERULUS FILTRATION; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSURIA; HEMODYNAMICS; HUMAN; HYPERTENSION; HYPOGLYCEMIA; KIDNEY FUNCTION; KIDNEY TUBULE; KIDNEY TUBULE ABSORPTION; MILD RENAL IMPAIRMENT; MODERATE RENAL IMPAIRMENT; PATHOGENESIS; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SEVERE RENAL IMPAIRMENT; URINARY EXCRETION; ANTAGONISTS AND INHIBITORS; DIABETIC NEPHROPATHIES; DRUG EFFECTS; METABOLISM; PATHOPHYSIOLOGY;

DIABETES MELLITUS; DIABETIC NEPHROPATHIES; GLUCOSE; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY GLOMERULUS; RENAL ELIMINATION; RENAL REABSORPTION; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84978790852     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-016-0379-5     Document Type: Review

References (84)

1. Bays H. Sodium glucose co-transporter type 2 (SGLT2) inhibitors: targeting the kidney to improve glycemic control in diabetes mellitus. Diabetes Ther. 2013;4(2):195–220.
2. Kalra S. Sodium glucose co-transporter-2 (SGLT2) inhibitors: a review of their basic and clinical pharmacology. Diabetes Ther. 2014;5(2):355–66.
3. Sha S, Devineni D, Ghosh A, et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab. 2011;13(7):669–72.
4. Zanoli L, Granata A, Lentini P, et al. Sodium-glucose linked transporter-2 inhibitors in chronic kidney disease. Sci World J. 2015;2015:6. doi:10.1155/2015/317507.
5. Rosenwasser RF, Sultan S, Sutton D, Choksi R, Epstein BJ. SGLT-2 inhibitors and their potential in the treatment of diabetes. Diabetes Metab Syndr Obes. 2013;6:453–67.
6. Gerich J. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabetic Med. 2010;27(2):136–42.
7. Cherney DZ, Scholey JW, Jiang S, et al. The effect of direct renin inhibition alone and in combination with ACE inhibition on endothelial function, arterial stiffness, and renal function in type 1 diabetes. Diabetes Care. 2012;35(11):2324–30 (Epub 2012/07/28).
8. De Nicola L, Gabbai FB, Liberti ME, Sagliocca A, Conte G, Minutolo R. Sodium/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes. Am J Kidney Dis. 2014;64(1):16–24.
9. Panchapakesan U, Pegg K, Gross S, et al. Effects of SGLT2 inhibition in human kidney proximal tubular cells—renoprotection in diabetic nephropathy? PLoS One. 2013;8(2):e54442.
10. Vallon V, Richter K, Blantz RC, Thomson S, Osswald H. Glomerular hyperfiltration in experimental diabetes mellitus potential role of tubular reabsorption. J Am Soc Nephrol. 1999;10(12):2569–76.
11. Mather A, Pollock C. Glucose handling by the kidney. Kidney Int. 2011;79:S1–6.
12. Wright EM, Turk E. The sodium/glucose cotransport family SLC5. Pflügers Archiv. 2004;447(5):510–8.
13. Wright EM. Renal Na+-glucose cotransporters. Am J Physiol Renal Physiol. 2001;280(1):F10–8.
14. Abdul-Ghani M, DeFronzo R. Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus. Endocr Pract. 2008;14(6):782–90.
15. DeFronzo R, Davidson J, Del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab. 2012;14(1):5–14.
16. Komoroski B, Vachharajani N, Boulton D, et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther. 2009;85(5):520–6.
17. Seman L, Macha S, Nehmiz G, et al. Empagliflozin (BI 10773), a potent and selective SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Drug Dev. 2013;2(2):152–61.
18. Grempler R, Thomas L, Klein T, et al. Weight loss induced by the potent and selective SGLT2 inhibitor, BI 10773, is due to body fat reduction. Studies in dietary-induced obese rats. Diabetes. In: Abstract 1793-P presented at the 70th Scientific Sessions of the American Diabetes Association, Orlando, FL, USA. 2010;59:469.
19. Bays HE, Weinstein R, Law G, Canovatchel W. Canagliflozin: effects in overweight and obese subjects without diabetes mellitus. Obesity. 2014;22(4):1042–9.
20. List JF, Whaley JM. Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans. Kidney Int. 2011;79:S20–7.
21. Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium–glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013;159(4):262–74.
22. Neumiller JJ. Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. Drugs Context. 2014;3(212262):10.7573.
23. Poole RM, Dungo RT. Ipragliflozin: first global approval. Drugs. 2014;74(5):611–7.
24. Nauck MA, Del Prato S, Meier JJ, et al. Dapagliflozin versus glipizide as add-on therapy in patients with Type 2 diabetes who have inadequate glycemic control with metformin a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care. 2011;34(9):2015–22.
25. Organisation CDsC. List of approved drug. http://cdsco.nic.in/. Accessed Dec 24, 2015. 2015.
26. Bailey C, Iqbal N, T’joen C, List J. Dapagliflozin monotherapy in drug-naïve patients with diabetes: a randomized-controlled trial of low-dose range. Diabetes Obes Metab. 2012;14(10):951–9.
27. Cefalu WT, Leiter LA, Yoon K-H, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. The Lancet. 2013;382(9896):941–50.
28. Devineni D, Morrow L, Hompesch M, et al. Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes Metab. 2012;14(6):539–45.
29. Ferrannini E, Seman L, Seewaldt-Becker E, Hantel S, Pinnetti S, Woerle H. A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes. Diabetes Obes Metab. 2013;15(8):721–8.
30. Stenlöf K, Cefalu W, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013;15(4):372–82.
31. Scheen AJ. Pharmacokinetics, Pharmacodynamics and clinical use of SGLT2 inhibitors in patients with Type 2 diabetes mellitus and chronic kidney disease. Clin Pharmacokinet. 2015;54(7):691–708.
32. Devineni D, Curtin CR, Marbury TC, et al. Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor. Clin Ther. 2015;37(3):610–28. e4.
33. Kasichayanula S, Liu X, Pe Benito M, et al. The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus. Br J Clin Pharmacol. 2013;76(3):432–44.
34. Kohan DE, Fioretto P, Tang W, List JF. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 2014;85(4):962–71.
35. Macha S, Mattheus M, Halabi A, Pinnetti S, Woerle H, Broedl U. Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment. Diabetes Obes Metab. 2014;16(3):215–22.
36. Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2013;15(5):463–73.
37. Cherney DZ, Perkins BA, Soleymanlou N, et al. The renal hemodynamic effect of SGLT2 inhibition in patients with type 1 diabetes. Circulation. 2013:CIRCULATIONAHA. 113.005081.
38. Giunti S, Barit D, Cooper ME. Mechanisms of diabetic nephropathy role of hypertension. Hypertension. 2006;48(4):519–26.
39. Van Buren PN, Toto R. Hypertension in diabetic nephropathy: epidemiology, mechanisms, and management. Adv Chronic Kidney Dis. 2011;18(1):28–41.
40. Cherney DZ, Scholey JW, Miller J. Insights into the regulation of renal hemodynamic function in diabetic mellitus. Curr Diabetes Rev. 2008;4(4):280–90.
41. Sasson AN, Cherney D. Renal hyperfiltration related to diabetes mellitus and obesity in human disease. World J Diabetes. 2012;3(1):1–6.
42. Jerums G, Premaratne E, Panagiotopoulos S, MacIsaac R. The clinical significance of hyperfiltration in diabetes. Diabetologia. 2010;53(10):2093–104.
43. Melsom T, Mathisen UD, Ingebretsen OC, et al. Impaired fasting glucose is associated with renal hyperfiltration in the general population. Diabetes Care. 2011;34(7):1546–51.
44. Magee GM, Bilous R, Cardwell CR, Hunter SJ, Kee F, Fogarty DG. Is hyperfiltration associated with the future risk of developing diabetic nephropathy? A meta-analysis. Diabetologia. 2009;52(4):691–7.
45. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861–9.
46. De Azevedo M, Ramos O, Gross J. Lack of effect of captopril on glomerular hyperfiltration in normoalbuminuric normotensive insulin-dependent diabetic patients. Horm Metab Res. 1997;29(10):516–9.
47. Ficociello LH, Perkins BA, Silva KH, et al. Determinants of progression from microalbuminuria to proteinuria in patients who have type 1 diabetes and are treated with angiotensin-converting enzyme inhibitors. Clin J Am Soc Nephrol. 2007;2(3):461–9 Epub 2007/08/19.
48. Sochett EB, Cherney DZ, Curtis JR, Dekker MG, Scholey JW, Miller JA. Impact of renin angiotensin system modulation on the hyperfiltration state in type 1 diabetes. J Am Soc Nephrol. 2006;17(6):1703–9.
49. Ismail N, Becker B, Strzelczyk P, Ritz E. Renal disease and hypertension in non-insulin-dependent diabetes mellitus. Kidney Int. 1999;55(1):1–28 (Epub 1999/01/20).
50. Keller CK, Bergis KH, Fliser D, Ritz E. Renal findings in patients with short-term type 2 diabetes. J Am Soc Nephrol. 1996;7(12):2627–35 (Epub 1996/12/01).
51. Association AD. Standards of medical care in diabetes—2013. Diabetes Care. 2013;36(Suppl 1):S11.
52. Terami N, Ogawa D, Tachibana H, et al. Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice. PLoS One. 2014;9(6):e100777.
53. Gembardt F, Bartaun C, Jarzebska N, et al. The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension. Am J Physiol Renal Physiol. 2014;307(3):F317–25.
54. Komala MG, Gross S, Mudaliar H, et al. Inhibition of kidney proximal tubular glucose reabsorption does not prevent against diabetic nephropathy in type 1 diabetic eNOS knockout mice. PLoS One. 2014;9(11):e108994.
55. Janssen Initiates CREDENCE Study in Patients with Type 2 Diabetes and Diabetic Nephropathy. http://www.investor.jnj.com/releasedetail.cfm?ReleaseID=827412. Accessed April 22, 2016.
56. Oliva RV, Bakris GL. Blood pressure effects of sodium–glucose co-transport 2 (SGLT2) inhibitors. J Am Soc Hypertens. 2014;8(5):330–9.
57. Weber MA, Mansfield TA, Iqbal N, Parikh SJ, Ptaszynska A. Dapagliflozin lowers HbA1c, systolic blood pressure and serum uric acid in patients with Type 2 diabetes and hypertension, regardless of class of concomitant antihypertensive therapy. Circulation. 2014;130(Suppl 2):A13640-A.
58. Lambers Heerspink H, De Zeeuw D, Wie L, Leslie B, List J. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab. 2013;15(9):853–62.
59. De Zeeuw D, Remuzzi G, Parving H-H, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int. 2004;65(6):2309–20.
60. Heerspink H, Johnsson E, Gause-Nilsson I, Cain V, Sjöström C. Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers. Diabetes Obes Metab. 2016;18(6):590–7.
61. Barnett AH, Mithal A, Manassie J, et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014;2(5):369–84.
62. Chonchol M, Shlipak MG, Katz R, et al. Relationship of uric acid with progression of kidney disease. Am J Kidney Dis. 2007;50(2):239–47.
63. Goicoechea M, de Vinuesa SG, Verdalles U, et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol. 2010;5(8):1388–93.
64. Iseki K, Oshiro S, Tozawa M, Iseki C, Ikemiya Y, Takishita S. Significance of hyperuricemia on the early detection of renal failure in a cohort of screened subjects. Hypertens Res. 2001;24(6):691–7.
65. Hovind P, Rossing P, Johnson RJ, Parving H-H. Serum uric acid as a new player in the development of diabetic nephropathy. J Ren Nutr. 2011;21(1):124–7.
66. Kang D-H, Nakagawa T, Feng L, et al. A role for uric acid in the progression of renal disease. J Am Soc Nephrol. 2002;13(12):2888–97.
67. Bjornstad P, Lanaspa MA, Ishimoto T, et al. Fructose and uric acid in diabetic nephropathy. Diabetologia. 2015;58(9):1993–2002.
68. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375(9733):2223–33.
69. Wilding J, Ferrannini E, Fonseca V, Wilpshaar W, Dhanjal P, Houzer A. Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study. Diabetes Obes Metab. 2013;15(5):403–9.
70. Usiskin K, Kline I, Fung A, Mayer C, Meininger G. Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: pooled analysis of phase 3 study results. Postgrad Med. 2014;126(3):16–34.
71. Leiter LA, Yoon K-H, Arias P, et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study. Diabetes Care. 2015;38(3):355–64.
72. Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products sparking the development of diabetic vascular injury. Circulation. 2006;114(6):597–605.
73. Hsieh C-L, Yang M-H, Chyau C-C, et al. Kinetic analysis on the sensitivity of glucose-or glyoxal-induced LDL glycation to the inhibitory effect of Psidium guajava extract in a physiomimic system. Biosystems. 2007;88(1):92–100.
74. Negre-Salvayre A, Salvayre R, Augé N, Pamplona R, Portero-Otin M. Hyperglycemia and glycation in diabetic complications. Antioxid Redox Signal. 2009;11(12):3071–109.
75. Maeda S, Matsui T, Takeuchi M. Yamagishi Si. Sodium-glucose cotransporter 2-mediated oxidative stress augments advanced glycation end products-induced tubular cell apoptosis. Diabetes Metab Res Rev. 2013;29(5):406–12.
76. Kojima N, Williams JM, Takahashi T, Miyata N, Roman RJ. Effects of a new SGLT2 inhibitor, luseogliflozin, on diabetic nephropathy in T2DN rats. J Pharm Exp Ther. 2013;345(3):464–72.
77. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28.
78. Schernthaner G, Schernthaner-Reiter MH, Schernthaner GH. EMPA-REG and other cardiovascular outcome trials of glucose-lowering agents: implications for future treatment strategies in Type 2 diabetes mellitus. Clin Ther. 2016;38(6):1288–98.
79. Nauck MA. Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug Des Dev Ther. 2014;8:1335.
80. Shawwa K EF, Samaha A. A case of Fanconi syndrome in a patient taking canagliflozin for diabetes: a previously unreported catastrophic adverse effect. Am J Kidney Dis 67(5):A99.
81. K/DOQI clinical practice guidelines for chronic kidney disease. evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 Suppl 1):S1–266 (Epub 2002/03/21).
82. (Invokana™) C. Prescribing Information. Titusville, NJ: Janssen Pharmaceuticals, Inc. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204042s000lbl.pdf. On April 22, 2016.
83. (JardianceTM) E. Prescribing information. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc. http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing+Information/PIs/Jardiance/jardiance.pdf. Accessed April 15, 2016.
84. Dapagliflozin (Farxiga™) Prescribing information. Wilmington DAhwa-ucppfppAoD, 2015. Prescribing information. Wilmington, Delaware: AstraZeneca. http://www1.astrazeneca-us.com/pi/pi_farxiga.pdf#page=1. Accessed April 22, 2016.